Market Overview

Aurora Cannabis Analyst Lifts Price Target As Company Nears German Regulatory Approval

Share:
Aurora Cannabis Analyst Lifts Price Target As Company Nears German Regulatory Approval
Read more about our latest Cannabis News! CANNABIS HOME

Aurora Cannabis Inc. (NYSE: ACB) is close to being awarded the maximum number of lots for domestic cannabis production in Germany. The deal's completion is subject to the finalization of an appeals process next week; Canaccord Genuity considers the process a moderate-to-high risk.

The Analyst

Matt Bottomley maintained a Speculative Buy rating on Aurora and raised the price target from CA$13 ($9.76) to CA$13.50 ($10.13).

The Thesis

The market potential in Germany could translate to long-term upside, according to Bottomley.

Germany's peak medical demand is double Canada's, with growing public acceptance and high reimbursement expected.

"We believe Aurora's receipt of this license adds incremental legitimacy to the overall international optionality secured by the company as of late," Bottomley wrote in a note.

The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian and many others.

Aurora made an impressive early start in Canada's adult use market, reporting recreational weed sales of CA$21.6 million in the second quarter, or 20-percent market share, Bottomley said. The company's sales volumes imply that Aurora earned a gross price of more than CA$6 per gram of dried flower and more than CA$10 per gram of oil, he said. If accurate, both figures exceed Cannacord's expectations.

The analyst also mentioned Aurora's multiple acquisitions in recent years, advising investors to keep a close eye on the integration of these products in future sales quarters.

Price Action

Aurora's stock traded around $9.04 at time of publication, down 1.4 percent.

Related Links:

Aphria, Aurora Cannabis, Wayland Group Win Public Tender To Grow Medical Marijuana In Germany

Aurora Cannabis Files Preliminary Prospectus To Raise Up To $750M

Latest Ratings for ACB

DateFirmActionFromTo
Jul 2019DowngradesBuyNeutral
Jul 2019Initiates Coverage OnBuy
Jun 2019Initiates Coverage OnHold

View More Analyst Ratings for ACB
View the Latest Analyst Ratings

Read more about our latest Cannabis News! CANNABIS HOME

Posted-In: Canaccord GenuityAnalyst Color Cannabis Price Target Reiteration Top Stories Markets Analyst Ratings Best of Benzinga

 

Related Articles (ACB)

View Comments and Join the Discussion!

Port Report: Japan's K Line Plans Review Of Its Sprawling Business Lines As Losses Mount

Daseke Execs Talk Acquisitions, Succession Planning And Letting Go Of The Family Business